Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BG Medicine to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, March 13, 2013

BGMD
BG Medicine to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, March 13, 2013

WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Wednesday, March 13 at 8:30 a.m. Eastern Time to discuss its fourth quarter and year-end 2012 financial results. The call and webcast will follow the release of the fourth quarter financial results before the market opens.

Conference Call Details

To access the live conference call on March 13 at 8:30 a.m. Eastern Time via phone, please dial (877) 845-1016 from the U.S. and Canada, or (708) 290-1155 internationally. Please dial in approximately ten minutes prior to the start of the call.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's website http://investor.bg-medicine.com/events.cfm. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About BG Medicine

BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the development and commercialization of novel cardiovascular tests to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The Company has two products: the BGM Galectin-3® test for use in patients with chronic heart failure is available in the United States and Europe; and the CardioSCORE™ test for the risk prediction of major cardiovascular events will be launched in Europe in the first half of 2013. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

CONTACT: Chuck Abdalian
         EVP & Chief Financial Officer
         (781) 434-0210

BG Medicine Inc. logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today